Overview

Study of Antibody for Methamphetamine Outpatient Therapy

Status:
Completed
Trial end date:
2021-03-09
Target enrollment:
Participant gender:
Summary
This study evaluates the ability of IXT-m200 to change methamphetamine concentrations in blood and alter the way methamphetamine feels. Participants will receive either placebo, a low or high dose of IXT-m200, in addition to methamphetamine challenge doses.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
InterveXion Therapeutics, LLC
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
Antibodies
Immunoglobulins
Methamphetamine